LLY

1,014.98

-0.96%↓

JNJ

240.9

+1.12%↑

ABBV

220.69

-0.72%↓

NVS

159.71

+1.01%↑

MRK

119.32

+1.9%↑

LLY

1,014.98

-0.96%↓

JNJ

240.9

+1.12%↑

ABBV

220.69

-0.72%↓

NVS

159.71

+1.01%↑

MRK

119.32

+1.9%↑

LLY

1,014.98

-0.96%↓

JNJ

240.9

+1.12%↑

ABBV

220.69

-0.72%↓

NVS

159.71

+1.01%↑

MRK

119.32

+1.9%↑

LLY

1,014.98

-0.96%↓

JNJ

240.9

+1.12%↑

ABBV

220.69

-0.72%↓

NVS

159.71

+1.01%↑

MRK

119.32

+1.9%↑

LLY

1,014.98

-0.96%↓

JNJ

240.9

+1.12%↑

ABBV

220.69

-0.72%↓

NVS

159.71

+1.01%↑

MRK

119.32

+1.9%↑

Search

OraSure Technologies Inc

Fechado

SetorSaúde

2.81 0.36

Visão Geral

Variação de preço das ações

24h

Atual

Mín

2.73

Máximo

2.86

Indicadores-chave

By Trading Economics

Rendimento

-30M

-14M

Vendas

27M

27M

Margem de lucro

-50.626

Funcionários

501

EBITDA

3.2M

-11M

Dividendos

By Dow Jones

Próximos Ganhos

25 de fev. de 2026

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

11M

206M

Abertura anterior

2.45

Fecho anterior

2.81

Sentimento de Notícias

By Acuity

50%

50%

149 / 352 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Strong Bearish Evidence

OraSure Technologies Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

11 de fev. de 2026, 23:47 UTC

Ações em Alta

Stocks to Watch: AppLovin, Cisco, Cognex, Pilgrim's Pride

11 de fev. de 2026, 22:59 UTC

Ganhos
Aquisições, Fusões, Aquisições de Empresas

Grab Holdings to Buy U.S.-Based Stash Financial

11 de fev. de 2026, 23:54 UTC

Ganhos

McDonald's Says Its Value Campaign Is Paying Off -- 2nd Update

11 de fev. de 2026, 23:50 UTC

Conversa de Mercado

Global Equities Roundup: Market Talk

11 de fev. de 2026, 23:50 UTC

Conversa de Mercado

Nikkei May Rise on Hopes for Takaichi's Economic Steps -- Market Talk

11 de fev. de 2026, 23:49 UTC

Ganhos

Singtel: Key Focus Areas Are Strengthening Core Businesses, Scaling Growth Engines, Building Momentum Across Regional Associates >Z74.SG

11 de fev. de 2026, 23:45 UTC

Ganhos

Singtel: Net Exceptional Gain of S$1.15B in 3Q Primarily From Sale of Partial Stake in Bharti Airtel>Z74.SG

11 de fev. de 2026, 23:42 UTC

Ganhos

Singtel 3Q Underlying Net Profit S$744M Vs. S$680M >Z74.SG

11 de fev. de 2026, 23:41 UTC

Ganhos

Singtel 3Q Net S$1.89B Vs. Net S$1.32B >Z74.SG

11 de fev. de 2026, 23:40 UTC

Ganhos

Singtel 3Q Operating Revenue S$3.66B Vs. S$3.63B >Z74.SG

11 de fev. de 2026, 23:35 UTC

Conversa de Mercado

Gold Falls on Prospects of Long Fed Pause -- Market Talk

11 de fev. de 2026, 23:18 UTC

Conversa de Mercado

AppLovin CEO Looks to Soothe Concerns Over AI, Competition -- Market Talk

11 de fev. de 2026, 23:14 UTC

Conversa de Mercado

RBA Governor Faces Barrage of Questions About Govt Spending -- Market Talk

11 de fev. de 2026, 22:59 UTC

Ganhos

Kakao 2025 Net KRW525.72B Vs. Loss KRW161.87B >035720.SE

11 de fev. de 2026, 22:59 UTC

Ganhos

Kakao 2025 Oper Pft KRW732.04B Vs. Pft KRW460.21B >035720.SE

11 de fev. de 2026, 22:59 UTC

Ganhos

Kakao 2025 Rev KRW8.099T Vs. KRW7.872T >035720.SE

11 de fev. de 2026, 22:58 UTC

Ganhos

Kakao 4Q Net Loss Missed FactSet-Compiled Consensus

11 de fev. de 2026, 22:57 UTC

Ganhos

Kakao 4Q Loss KRW39.30B Vs. Loss KRW395.21B >035720.SE

11 de fev. de 2026, 22:54 UTC

Ganhos

Kakao 4Q Oper Pft KRW203.45B Vs. Pft KRW75.43B >035720.SE

11 de fev. de 2026, 22:53 UTC

Ganhos

Kakao 4Q Rev KRW2.133T Vs. KRW1.957T >035720.SE

11 de fev. de 2026, 22:47 UTC

Ganhos

AppLovin Reports Strong Earnings. The Stock Is Down. -- Barrons.com

11 de fev. de 2026, 22:47 UTC

Ganhos

AppLovin Reports Strong Earnings. The Stock Is Down. -- Barrons.com

11 de fev. de 2026, 22:23 UTC

Ganhos

Grab Holdings Expects to Close Stash Acquisition in 3Q of 2026 >GRAB

11 de fev. de 2026, 22:22 UTC

Ganhos

Grab Holdings to Acquire U.S. Digital Financial Services Company Stash Financial >GRAB

11 de fev. de 2026, 22:22 UTC

Ganhos

Grab Holdings Sees FY26 Adj Ebitda $700M to $720M >GRAB

11 de fev. de 2026, 22:19 UTC

Ganhos

Grab Holdings Sees FY26 Rev $4.04B to $4.10B >GRAB

11 de fev. de 2026, 22:18 UTC

Ganhos

Grab Holdings 4Q Adj Ebitda $148.0M Vs. $97.0M >GRAB

11 de fev. de 2026, 22:18 UTC

Ganhos

Grab Holdings 4Q Net $153.0M Vs. Net $11.0M >GRAB

11 de fev. de 2026, 22:18 UTC

Ganhos

Grab Holdings 4Q Oper Pft $52.0M Vs. $2.0M >GRAB

11 de fev. de 2026, 22:16 UTC

Ganhos

Grab Holdings 4Q Rev $906.0M Vs. $764.0M >GRAB

Comparação entre Pares

Variação de preço

OraSure Technologies Inc Previsão

Consenso de Avaliação

By TipRanks

0 ratings

0

Comprar

0

Manter

0

Vender

Pontuação Técnica

By Trading Central

N/A / 2.975Suporte e Resistência

Curto Prazo

Strong Bearish Evidence

Médio Prazo

Weak Bearish Evidence

Longo Prazo

No Evidence

Sentimento

By Acuity

149 / 352 Ranking em Saúde

Sentimento de Notícias

Neutral

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Abaixo da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre OraSure Technologies Inc

OraSure Technologies, Inc., together with its subsidiaries, provides point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services in the United States, Europe, and internationally. The company's products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D. saliva alcohol test. It also offers genomic products under the Oragene and ORAcollect brands for collecting genetic material from human saliva; Colli-Pee collection devices for the volumetric collection of void urine samples; and microbiome laboratory testing and analytical services. In addition, the company provides microbiome products, such as OMNIgene GUT for self-collecting microbial DNA from feces or stool samples for gut microbiome profiling; OMNIgene GUT DNA and RNA collection devices; and OMNIgene GUT Dx collection device for collection of human fecal samples and the stabilization of DNA from the bacterial community. Additionally, it provides other diagnostic products, such as immunoassays and other in vitro diagnostic tests. The company markets its products to clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations, distributors, government agencies, physicians' offices, commercial and industrial entities, disease risk management, diagnostics, pharmaceutical, biotech, nutrition, companion animal, and environmental markets. OraSure Technologies, Inc. was incorporated in 2000 and is based in Bethlehem, Pennsylvania.
help-icon Live chat